| Literature DB >> 33907472 |
Demeke Dejen1, Dube Jara2, Fanos Yeshanew3, Zinabu Fentaw4, Tesfa Mengie Feleke5, Fentaw Girmaw6, Birhanu Wagaye3.
Abstract
INTRODUCTION: There is an expansion and advancement of antiretroviral therapy. However, attrition of patients from HIV care is one of the major drivers of poor performance of HIV/AIDS programs, which leads to drug resistance, morbidity and mortality. The study aimed to assess the incidence of attrition and its predictors among adults receiving first-line antiretroviral therapy.Entities:
Keywords: Ethiopia; HIV/AIDS; antiretroviral therapy; attrition; retrospective cohort
Year: 2021 PMID: 33907472 PMCID: PMC8068483 DOI: 10.2147/HIV.S304657
Source DB: PubMed Journal: HIV AIDS (Auckl) ISSN: 1179-1373
Figure 1Profiles of HIV/AIDS clients in Woldia Town Public Health Facilities (February 1, 2014 to January 31, 2020) Northeast Ethiopia; 2020.
Sociodemographic and Behavioral Characteristic of Adults Receiving ART Related with Attrition in Woldia Town Public Health Facilities, Northeast Ethiopia 2020, n=634
| Variables | Categories | Total (%) |
|---|---|---|
| Sex of respondent | Female | 345 (54.4) |
| Male | 289 (45.6) | |
| Age of respondent | 15–24 years | 80 (12.6) |
| 25–34 years | 248 (39.1) | |
| 35–44 years | 172 (27.1) | |
| ≥45 years | 134 (21.1) | |
| Residence of client | Urban | 354 (55.8) |
| Rural | 280 (44.2) | |
| Religion | Orthodox Christian | 518 (81.7) |
| Muslim | 116 (18.3) | |
| Educational status | Unable to read and write | 271 (42.7) |
| Primary | 201 (31.7) | |
| Secondary & above | 162 (25.6) | |
| Occupational status | Employed a | 121 (19.1) |
| Farmer b | 250 (39.4) | |
| Unemployed c | 263 (41.5) | |
| Marital status | Never married | 130 (20.5) |
| Married | 310 (48.9) | |
| Others d | 194 (30.6) | |
| Disclosure status | Yes | 470 (74.1) |
| No | 164 (24.9) | |
| Adherence level | Good | 413 (65.1) |
| Fair | 139 (21.9) | |
| Poor | 82 (12.9) | |
| Substance use | Yes | 88 (13.9) |
| No | 546 (86.1) |
Notes: aPrivate sector servant, civil servant and merchant; bFarmer and house wife; cStudent, daily laborer and unemployed; dDivorced, separated and widowed.
Baseline Clinical and Health System Characteristics Among Adult Clients Who Were Receiving ART in Woldia Town Public Health Facilities, 2020, (n=634)
| Variables | Category | Total (%) |
|---|---|---|
| ART linkage pointa | VCT* | 264 (41.6) |
| OPD/IPD* | 205 (32.3) | |
| MCH/Othersa | 165 (26.0) | |
| Year of ART initiation | 2014–2016 | 329 (51.9) |
| 2017–2018 | 227 (35.8) | |
| 2019–2020 | 78 (12.3) | |
| BMI | <18.5 kg/m2 | 206 (32.5) |
| ≥18.5 kg/m2 | 428 (67.5) | |
| Functional status | Working | 476 (75.1) |
| Ambulatory | 104 (16.4) | |
| Bedridden | 54 (8.5) | |
| WHO clinical stage | Stage I | 252 (39.7) |
| Stage II | 187 (29.5) | |
| Stage III | 152 (24.0) | |
| Stage IV | 43 (6.8) | |
| TB treatment at baseline | Yes | 69 (10.9) |
| No | 565 (89.1) | |
| IPT* treatment at baseline | Yes | 313 (49.4) |
| No | 321 (50.6) | |
| Baseline CD4 count | Not recorded | 134 (21.1) |
| ≤350 | 306 (48.3) | |
| >350 | 194 (30.6) | |
| VL* count at ≥ 6 month | ≤1000 | 425 (67.0) |
| >1000/no record | 209 (33.0) | |
| Baseline Hemoglobin | Not recorded | 324 (51.1) |
| ≤10 | 59 (9.3) | |
| >10 | 251 (39.6) | |
| Cotrimoxazole Preventive Therapy (CPT) at baseline | Yes | 372 (58.7) |
| No | 262 (41.3) | |
| NRTI at baseline | TDF containing | 586 (92.4) |
| AZT/ABC containing | 48 (7.6) | |
| NNRTI/INSTI* at baseline | DTG | 49 (7.7) |
| EFV | 531 (83.8) | |
| NVP | 54 (8.5) | |
| OI* presence | Yes | 132 (20.8) |
| No | 502 (79.2) | |
| Mental illness | Yes | 36 (5.7) |
| No/no record | 598 (94.3) | |
| Client is on ASM* | Yes | 159 (25.1) |
| No | 475 (74.9) | |
| Drug side effect/toxicity | Yes | 79 (12.5) |
| No | 555 (87.5) |
Note: aClients linked to ART other than VCT, OPD, IPD like MCH, youth-friendly service.
Abbreviations: *INSTI, integrase strand transfer inhibitor (also known as integrase inhibitors); *IPT, isoniazid preventive therapy, VL*, viral load; OI*, opportunistic infection ASM*, appointment spacing modeling; VCT*, voluntary counseling and testing; OPD*, out patient; IPD*, in patient department; MCH*, maternal and child health.
Figure 2Kaplan–Meier failure estimates by failure function of attrition among adult patients on ART in Woldia Town, Northeast Ethiopia, 2020.
Figure 3Kaplan–Meier failure estimates of attrition by baseline WHO stage among adult patients on ART in Woldia Town, Northeast Ethiopia, 2020.
Figure 4Kaplan–Meier failure estimates of attrition by adherence level among adult patients on ART in Woldia Town Public Health Facilities, Northeast Ethiopia, 2020.
Predictors of Attrition Among Patients with HIV/AIDS Receiving ART in Woldia Town Public Health Facilities, January 2020
| Predictors | Censored (%) | Attrition (%) | Crude HR 95% CI | Adjusted HR95% CI |
|---|---|---|---|---|
| Age of respondent | ||||
| 15−24 | 49 (7.7) | 31 (4.9) | 2.82 (1.69−4.70) | 2.0 (1.11−3.58)** |
| 25−34 | 209 (33.0) | 39 (6.2) | 1.01 (0.62− 1.64) | 0.72 (0.42−1.24) |
| 35−44 | 144 (22.7) | 28 (4.4) | 1.000 | 1.000 |
| ≥45 | 81 (12.8) | 53 (8.3) | 2.87 (1.82−4.55) | 1.45 (0.84−2.49) |
| Year of enrolment | ||||
| 2014−2016 | 244 (38.4) | 85 (13.4) | 1.000 | 1.000 |
| 2017−2018 | 176 (27.8) | 51 (8.0) | 1.35 (0.94–1.96) | 1.50 (0.96−2.37) |
| 2019−2020a | 63 (9.9) | 15 (2.4) | 1.93 (1.08–3.44) | 2.32 (1.08–5.01)** |
| BMI in kg/m2 | ||||
| <18.5 | 114 (18.1) | 92 (14.5) | 4.03 (2.90−5.60) | 0.91 (0.55–1.49) |
| ≥18.5 | 369 (58.2) | 59 (9.3) | 1.000 | 1.000 |
| Functional status | ||||
| Working | 432 (68.1) | 44 (6.9) | 1.000 | 1.000 |
| Ambulatory | 45 (7.1) | 59 (9.3) | 8.94 (6.03−13.24) | 1.46 (0.80−2.67) |
| Bedridden | 6 (0.9) | 48 (7.6) | 28.16 (18.24–43.48) | 3.25 (1.33−7.96)** |
| WHO stage | ||||
| Stage I | 241 (38.0) | 11 (1.7) | 1.000 | 1.000 |
| Stage II | 157 (24.8) | 30 (4.7) | 3.59 (1.80−7.16) | 1.75 (0.82−3.71) |
| Stage III | 78 (12.3) | 74 (11.7) | 15.83 (8.39−29.86) | 3.57 (1.58−8.06)*** |
| Stage IV | 7 (1.1) | 36 (5.7) | 45.81 (23.12−90.74) | 5.46 (1.97−15.13)*** |
| Baseline TB Rx | ||||
| Yes | 31 (4.9) | 38 (6.0) | 3.70 (2.56−5.36) | 0.70 (0.48−1.13) |
| No | 452 (71.3) | 113 (17.8) | 1.000 | 1.000 |
| IPT Rx at baseline | ||||
| Yes | 291 (46.0) | 22 (3.3) | 6.72 (4.27–10.56) | 1.68 (0.99–2.86) |
| No | 192 (30.3) | 129 (20.3) | 1.000 | 1.000 |
| Viral load count | ||||
| ≤1000 | 407 (64.2) | 18 (2.7) | 0.03 (0.02–0.05) | 0.11 (0.06−0.23)*** |
| >1000 | 76 (12.0) | 133 (21.0) | 1.000 | 1.000 |
| Presence of OI | ||||
| Yes | 60 (9.5) | 72 (11.3) | 5.26 (3.81−7.27) | 1.19 (0.71−1.97) |
| No | 423 (66.7) | 79 (12.5) | 1.000 | 1.000 |
| Disclosure status | ||||
| Yes | 429 (67.7) | 41 (6.4) | 1.000 | 1.000 |
| No | 54 (8.5) | 110 (17.4) | 12.20 (8.49−17.55) | 2.03 (1.22−3.37)*** |
| Adherence label | ||||
| Good | 389 (61.4) | 24 (3.7) | 1.000 | 1.000 |
| Fair | 73 (11.5) | 66 (10.4) | 10.23 (6.41− 16.34) | 1.86 (1.01−3.43)** |
| Poor | 21 (3.3) | 61 (9.6) | 24.72 (15.30−39.93) | 3.19 (1.67−6.09)*** |
| ASM | ||||
| Yes | 152 (24.0) | 7 (1.1) | 1.000 | 1.000 |
| No | 331 (52.3) | 144 (22.6) | 9.40 (4.40−20.11) | 1.28 (0.54–3.06) |
Notes: **p<0.05 at multivariate analysis; ***p<0.001 at multivariate analysis; Model fitness was checked using global test for proportional hazard assumption, the P value was 0.355 and the model was fitted; a2019–2020, recent calendar year is patients who were initiated ART drug in 2019 till the end of study periods.